Market withdrawal of Vioxx: is it time to rethink the use of COX-2 inhibitors?
Ortiz
Eduardo
E
D002318:Cardiovascular Diseases / Q000139:chemically induced*; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D006801:Humans; D007527:Isoenzymes; D007783:Lactones / Q000009:adverse effects*; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases; D013450:Sulfones / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D007783:Lactones; D008565:Membrane Proteins; D013450:Sulfones; C116926:rofecoxib; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases